Tharimmune licenses oral infliximab from Intract Pharma for global development

Canton Strategic Holdings, Inc.

Exclusive global license (ex-South Korea) to INT-023/TH023, an oral anti-TNF-α monoclonal antibody infliximab.
Intract received upfront payment, eligible for equity-linked payments, milestones, and mid-single-digit royalties on net sales.
Tharimmune holds right of first refusal to continue development after Phase 2 trial.
Option to license Intract's Soteria/Phloral platform for up to four additional targets.
Oral formulation aims to replace IV infliximab (Remicade) for autoimmune diseases; multibillion-dollar market opportunity cited.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.